非酒精性脂肪性肝病主要急性心血管事件预测的心血管风险评分推导与验证:平均血小板体积升高的重要性
本研究通过回顾性推导队列(2008-2016年,356例)和前瞻性验证队列(2016-2017年,111例)建立非酒精性脂肪性肝病(NAFLD)患者的心血管风险评分。推导队列主要急性心血管事件(MACE)发生率为12.6%,验证队列为12%。年龄、糖尿病和平均血小板体积(MPV)为MACE的独立预测因素,所建NAFLD CV-risk评分及MPV的预测效能优于Qrisk2和Framingham评分。
要点
- NAFLD CV-risk评分公式:0.06×年龄+0.963×MPV+0.26×糖尿病状态-16.44(糖尿病:有=1,无=2),AUROC 0.84。
- 评分截断值-3.98时灵敏度97%、特异度27%、PPV 16%、NPV 99%;MPV>10.05时灵敏度97%、特异度59%、PPV 24%、NPV 97%。
- 验证队列中NAFLD CV-risk评分AUROC为0.77,MPV为0.72,二者在全队列中均优于Qrisk2和Framingham评分。
核心结论
- NAFLD CV-risk评分和MPV能准确预测NAFLD患者1年MACE风险,有助于更好识别需要优化心血管风险谱的患者。
研究设计与样本
- 回顾性推导队列(2008-2016年,356例NAFLD患者)和前瞻性验证队列(2016-2017年,111例NAFLD患者)的队列研究。
主要发现
- 推导队列MACE发生率为12.6%,验证队列为12%,两队列匹配良好。
- 单因素分析显示年龄、糖尿病、进展期纤维化、胶原比例面积>5%、MPV和肝脏硬度与MACE相关。
- 多因素分析后,年龄、糖尿病和MPV仍为MACE的独立预测因素。
- 推导队列中NAFLD CV-risk评分AUROC为0.84,MPV单独AUROC为0.83;验证队列中二者AUROC分别为0.77和0.72。
- 全队列中NAFLD CV-risk评分和MPV的预测效能均优于Qrisk2和Framingham评分。
关键数值与推荐
- NAFLD CV-risk评分=0.06×年龄+0.963×MPV+0.26×糖尿病状态-16.44(糖尿病:有=1,无=2)。
- 评分截断值-3.98对应灵敏度97%、特异度27%、PPV 16%、NPV 99%。
- MPV>10.05对应灵敏度97%、特异度59%、PPV 24%、NPV 97%(AUROC 0.83)。
临床怎么用
- 原文未据此给出具体临床推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Atherosclerotic cardiovascular disease is a key cause of morbidity in non-alcoholic fatty liver disease (NAFLD) but appropriate means to predict major acute cardiovascular events (MACE) are lacking. AIM: To design a bespoke cardiovascular risk score in NAFLD. METHODS: A retrospective derivation (2008-2016, 356 patients) and a prospective validation (2016- 2017, 111 patients) NAFLD cohort study was performed. Clinical and biochemical data were recorded at enrolment and mean platelet volume (MPV), Qrisk2 and Framingham scores were recorded one year prior to MACE (Cardiovascular death, acute coronary syndrome, stroke and transient ischaemic attack). RESULTS: The derivation and validation cohorts were well-matched, with MACE prevalence 12.6% and 12%, respectively. On univariate analysis, age, diabetes, advanced fibrosis, collagen proportionate area >5%, MPV and liver stiffness were associated with MACE. After multivariate analysis, age, diabetes and MPV remained independently predictive of MACE. The "NAFLD CV-risk score" was generated using binary logistic regression: 0.06*(Age) + 0.963*(MPV) + 0.26*(DM1 ) - 16.44; 1 Diabetes mellitus: 1: present; 2: absent. (AUROC 0.84). A cut-off of -3.98 gave a sensitivity 97%, specificity 27%, PPV 16%, and NPV 99%. An MPV alone of >10.05 gave a sensitivity 97%, specificity 59%, PPV 24% and NPV 97% (AUROC 0.83). Validation cohort AUROCs were comparable at 0.77 (NAFLD CV-risk) and 0.72 (MPV). In the full cohort, the NAFLD CV-risk score and MPV outperformed both Qrisk2 and Framingham scores. CONCLUSIONS: The NAFLD CV risk score and MPV accurately predict 1-year risk of MACE, thereby allowing better identification of patients that require optimisation of their cardiovascular risk profile.
引用
- Abeles RD, Mullish BH, Forlano R, et al. Derivation and validation of a cardiovascular risk score for prediction of major acute cardiovascular events in non-alcoholic fatty liver disease; the importance of an elevated mean platelet volume. Aliment Pharmacol Ther. 2019. PMID: 30836450. doi:10.1111/apt.15192
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。